Edgewater Networks Announces Certification of VTech SIP ErisTerminal® SIP Deskset Phones and ErisStation® SIP Conference Phones
Edgewater Networks, the leader in Network Edge Orchestration, today announced that it has certified its Network Edge Orchestration platform with ErisTerminal® SIP deskset phones and ErisStation® SIP conference phones from VTech Communications, Inc., a global leader and manufacturer of SIP-based phones. VTech-certified models include VSP736, VSP608, VSP600, VSP726, VSP715, and VCS754 in a Broadsoft®-hosted environment. The results are documented in a standard configuration guide for easy deployment and integration.
Jennifer Kidd, VP of Business Development and head of the QuickConnect Interoperability Lab at Edgewater Networks, says, “The VTech line of desksets and conference phones offer numerous features and a user-friendly interface. At Edgewater Networks, we are pleased to enhance the functionality of this equipment with the guarantee that it will interoperate with Edgewater Networks Intelligent Edges immediately once installed. This will deliver enhanced call quality, security, and analytics to an already exceptional endpoint.”
VTech is the world’s No. 1 manufacturer of cordless phones, an expertise that spills over into its portfolio of cost-effective, cutting-edge business phone solutions. The company’s award-winning SIP systems scale anywhere from the one-man show in a home office to enterprise-level corporations. VTech SIP phones feature compatibility with hosted and open-source PBX platforms, U.S.-based support and best-in-class warranties.
“Our certification with Edgewater Networks will help bring our joint customers a more optimized experience with increased productivity in virtually any workplace,” says Ernie Levenson, president, VTech Communications, Inc. “VTech SIP phones ensure businesses experience clear and crisp desk and conference calls.”
Intelligent Edges are a key component in the Edgewater Networks’ Network Edge Orchestration platform. The Intelligent Edge ties service providers directly into the equipment at the edge of their networks, allowing them to perform continuous analytics, mitigate cyberattacks, and conduct automated call shaping to bolster QoS. Devices such as ErisTerminal SIP deskset phones and ErisStation conference phones are connected directly to EdgeMarc Intelligent Edges, letting service providers control, monitor, and provision those devices through the cloud-based EdgeView Service Control Center.
About Edgewater Networks, Inc.
Founded in October 2002, Edgewater Networks is a market leader in enabling IP-based voice, video and data services. Service providers and enterprises of all sizes use Edgewater Networks’ solutions to simplify customer premises configurations for quick and smooth installations, reduce time to market and deliver rapid return on invested capital. The company helps customers deliver intelligence at the network edge with its Network Edge Orchestration platform that includes the EdgeView Service Control Center and EdgeMarc Intelligent Edges. To learn more, please visit www.edgewaternetworks.com or follow us on Twitter at @ewn_inc.
About VTech
VTech provides a full portfolio of strong brands and a diverse collection of telecommunications products that elevate the business customer and hotel guest experience through state-of-the-art technology. They are sold through a wide network of trusted partners and are backed by industry-leading warranties and U.S.-based training and support. The company has recently added an award-winning collection of SIP phone systems, featuring compatibility with hosted and open-source PBX platforms.
Founded in 1976, VTech is the world’s largest manufacturer of cordless phones and the global leader in electronic learning products from infancy through toddler and preschool. It also provides highly sought-after contract manufacturing services. VTech’s mission is to design, manufacture and supply innovative and high-quality products, while creating sustainable value for its stakeholders and the community. For more information, please visit businessphones.vtech.com.
VTech® is a registered trademark of VTech Holdings Limited. ErisTerminal® and ErisStation® are registered trademarks of VTech Communications, Inc.
BroadSoft is a registered trademark of BroadSoft, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170912005397/en/
Contact information
Edgewater Networks
Jennifer Kidd
VP of Business Development
jkidd@edgewaternetworks.com
www.edgewaternetworks.com
or
VTech
Media
Stephanie Fazio, 503-596-1248
Advertising & Public
Relations Manager
sfazio@vtechphones.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom